These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26181273)

  • 1. Error in Table Text. Five Years of Cancer Drug Approvals: Innovation Efficacy and Costs.
    JAMA Oncol; 2015 Jul; 1(4):544. PubMed ID: 26181273
    [No Abstract]   [Full Text] [Related]  

  • 2. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
    Mailankody S; Prasad V
    JAMA Oncol; 2015 Jul; 1(4):539-40. PubMed ID: 26181265
    [No Abstract]   [Full Text] [Related]  

  • 3. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
    Lanthier M; Miller KL; Nardinelli C; Woodcock J
    Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The characteristics and fulfillment of conditional prescription drug approvals in Canada.
    Law MR
    Health Policy; 2014 Jun; 116(2-3):154-61. PubMed ID: 24703857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
    Kaitin KI; DiMasi JA
    Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring progress in neglected disease drug development.
    Cohen JP; Sturgeon G; Cohen A
    Clin Ther; 2014 Jul; 36(7):1037-42. PubMed ID: 24906971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomedical innovation: a risky business at risk.
    Stack RS; Harrington RA
    Sci Transl Med; 2011 Aug; 3(96):96cm23. PubMed ID: 21849662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
    Boon WP; Moors EH; Meijer A; Schellekens H
    Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2003 approvals: a year of innovation and upward trends.
    Frantz S
    Nat Rev Drug Discov; 2004 Feb; 3(2):103-5. PubMed ID: 15040573
    [No Abstract]   [Full Text] [Related]  

  • 14. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adoption of pharmaceutical innovation and its impact on the treatment costs for Alzheimer's disease in Taiwan.
    Lo TF; Hsieh CR
    J Ment Health Policy Econ; 2014 Sep; 17(3):107-17. PubMed ID: 25543114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methuselah's medicine: pharmaceutical innovation and mortality in the United States, 1960-2000.
    Schnittker J; Karandinos G
    Soc Sci Med; 2010 Apr; 70(7):961-8. PubMed ID: 20100632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes supporting anticancer product approvals.
    Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
    J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression biomarkers for clinical efficacy and outcome prediction in cancer.
    Strand KJ; Khalak H; Strovel JW; Ebner R; Augustus M
    Pharmacogenomics; 2006 Jan; 7(1):105-15. PubMed ID: 16354128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of 10 years drug lifecycle management (LCM) activities in the Japanese market.
    Hashitera Y; Saotome C; Yamamoto H
    Drug Discov Today; 2013 Nov; 18(21-22):1109-16. PubMed ID: 23856327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology.
    van der Greef J; McBurney RN
    Nat Rev Drug Discov; 2005 Dec; 4(12):961-7. PubMed ID: 16341061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.